Proteomics Approaches Used to Investigate Age Related Macular Degeneration.

Victor T Njoku, Antea Metaliaj, Costel C Darie, Timothy Blenkinsop, Aurelian Radu

Abstract readReview

In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Victor T Njoku *Biochemistry and Proteomics Laboratories, Department of Chemistry and Biochemistry, Clarkson University, Potsdam, NY, 13699-5810, USA.

Antea Metaliaj *New York Institute of Technology, 1855 Broadway, New York, NY, 10023, USA.

Costel C DarieBiochemistry and Proteomics Laboratories, Department of Chemistry and Biochemistry, Clarkson University, Potsdam, NY, 13699-5810, USA.

Timothy BlenkinsopDepartment of Stem Cell and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Aurelian RaduDepartment of Stem Cell and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related macular degeneration (AMD) affects a very large proportion of the elderly population, leading to progressive loss of vision. For the most frequent form of the disease, dry AMD, no effective therapies exist. This is a consequence of the fact that the mechanisms that lead to dry AMD are not understood. Among the many strategies used to accomplish this unmet need, valuable insights were provided by proteomics studies of biological fluids and of the eye cells affected by the disease. We review here the proteomics methods used by these studies, compare their advantages and limitations, and present the biologically relevant information produced by each method. We emphasize that proteomics methods continue to have high potential for this research area and are expected to lead to substantial progress towards understanding and curing AMD.

Indexed as

Eye ProteinsMacular DegenerationProteomeProteomicsAnimalsBiomarkersHumansMass SpectrometryBiomarkersEye ProteinsProteomeAge-related macular degenerationBiomarkersMass spectrometryProteomics

Identifiers

PMID42907641

DOI10.1038/s41593-021-00999-y

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.